My Treatment Approach: Acute Myeloid Leukemia (AML)

Richard Stone, MD, and Eunice Wang, MD, define secondary acute myeloid leukemia treatment goals and how treatment has been affected by the COVID-19 pandemic.

Two experts review a patient profile and discuss whether the patient meets the criteria for secondary acute myeloid leukemia (AML).

Richard Stone, MD, and Eunice Wang, MD, comment on the role of CPX-351 in the treatment of secondary AML and offer practice pointers for treatment with this drug, including management of adverse events.

Richard Stone, MD, and Eunice Wang, MD, provide an overview of how patients with AML are selected for treatment with CPX-351 or the combination of venetoclax-azacitidine.

Richard Stone, MD, and Eunice Wang, MD, discuss considerations and challenges related to the administration of venetoclax and azacitidine in the community setting, and share strategies for managing adverse events associated with this combination.

Two experts discuss the clinical implications of minimal residual disease (MRD) and how it has affected treatment for patients with acute myeloid leukemia (AML).

Drs Richard Stone and Eunice Wang review the clinical profile of a 67-year-old man with newly diagnosed acute myeloid leukemia (AML) and an IDH2 mutation.

Richard Stone, MD, and Eunice Wang, MD, explain how molecular biomarker testing influences their treatment decision-making in patients with acute myeloid leukemia (AML).

An overview of treatment options in patients who present with IDH1/IDH2 mutations and how to manage treatment-related adverse events.

Richard Stone, MD, and Eunice Wang, MD, share upcoming treatment advances they look forward to for patients with acute myeloid leukemia (AML).